Patients must express PPARG in at least 60 percent of tumor cells to enroll in the trial and receive the investigational drug.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

The operating efficiency effort includes "employment-related and other operating expense reductions in early research," the firm said.

Researchers at Stanford and St. Jude aim to bring PGx resources under one new umbrella and accelerate the discipline's ...

If a progression-free survival readout later this year is positive, the firm will pursue approval in HLA-A2-negative metastatic uveal melanoma.

The OVATION-3 trial is designed to provide an early readout in HRD and BRCA1/2-mutated ovarian cancer patients, ideally leading to rapid filing and approval.